PMID- 25605342
OWN - NLM
STAT- MEDLINE
DCOM- 20151228
LR  - 20181202
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 25
IP  - 3
DP  - 2015 Mar
TI  - [Negative effects on sexual function of medications for the treatment of lower 
      urinary tract symptoms related to benign prostatic hyperplasia].
PG  - 115-27
LID - S1166-7087(14)00690-3 [pii]
LID - 10.1016/j.purol.2014.12.003 [doi]
AB  - PURPOSE: The aim of this review is to discuss the negative effects on sexual 
      function of medications for lower urinary tract symptoms secondary to benign 
      prostatic hyperplasia (LUTS-BPH). METHODS: An international non-systematic 
      literature review was performed. It included randomized trials of seven drugs of 
      interest and the summaries of the characteristics of these products. This work 
      did not aim comparison between the drugs. RESULTS: Only maximal reported 
      frequencies are presented in this abstract. With prolonged-release alfuzosin, 
      they were 2.8% vs. 1.3% for erectile dysfunction, compared to placebo and 1% vs. 
      0% for ejaculatory dysfunction. With doxazosin, the incidence was 5.8% vs. 3.3% 
      for erectile dysfunction, 3.6% vs. 1.9% for reduced libido and 0.4% vs. 1.4% for 
      ejaculatory disorders. The incidence of ejaculatory disorders with tamsulosin, 
      was 11% vs. <1% with the placebo and with silodosin, it was 28.1% vs. 1.1%. With 
      finasteride, at 12 months, the highest frequency was 9% vs. 5% for erectile 
      dysfunction, 4.4% vs. 1.5% for ejaculatory disorders and 6.4% vs. 3.4% for 
      reduced libido. At 24 months, for dutatsteride, frequencies were 7.3% vs. 4.0% 
      for erectile dysfunction, 2.2% vs. 0.8% for ejaculatory disorders and 4.2% vs. 
      2.1% for reduced libido. For tadalafil, a phosphodiesterase-5 inhibitor, and 
      tolerodine, an anticholinergic drug, no negative effect on ejaculation or libido 
      has been reported. For plant extracts, no sexual adverse effects (AEs) were 
      reported among the most common AEs. CONCLUSION: The medications for LUTS-BPH may 
      alter erection, ejaculation or libido. A greater knowledge of the adverse effects 
      of each of these drugs could guide physicians in the clinical management of men 
      with BPH-LUTS.
CI  - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
FAU - Descazeaud, A
AU  - Descazeaud A
AD  - Service de chirurgie urologique, CHU de Limoges, 87042 Limoges cedex, France. 
      Electronic address: aureliendescazeaud@gmail.com.
FAU - de La Taille, A
AU  - de La Taille A
AD  - Service d'urologie, faculte de medecine de Creteil, groupe hospitalier 
      Henri-Mondor, 94000 Creteil, France.
FAU - Giuliano, F
AU  - Giuliano F
AD  - Service de medecine physique et de readaptation, faculte des sciences de la 
      sante, universite de Versailles Saint-Quentin en Yvelines, hopital 
      Raymond-Poincare, 92380 Garches, France.
FAU - Desgrandchamps, F
AU  - Desgrandchamps F
AD  - Service d'urologie et de transplantation, hopital Saint-Louis, universite Paris 
      7, institut des maladies emergentes et des therapies innovantes (iMETI), 75010 
      Paris, France.
FAU - Doridot, G
AU  - Doridot G
AD  - 24, boulevard Vital-Bouhot, 92521 Neuilly-Sur-Seine cedex, France.
LA  - fre
PT  - Journal Article
PT  - Review
PT  - Systematic Review
TT  - Effets negatifs sur la sexualite des traitements medicamenteux des symptomes du 
      bas appareil urinaire lies a l'hypertrophie benigne de la prostate.
DEP - 20150117
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Adrenergic alpha-Antagonists)
SB  - IM
MH  - Adrenergic alpha-Antagonists/adverse effects
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy/etiology
MH  - Male
MH  - Prostatic Hyperplasia/complications
MH  - Sexual Dysfunction, Physiological/*chemically induced
OTO - NOTNLM
OT  - 5-alpha-reductase inhibitors
OT  - Alpha-blockers
OT  - Alpha-bloquants
OT  - Benign prostatic hyperplasia
OT  - Dysfonction erectile
OT  - Ejaculatory dysfunction
OT  - Erectile dysfunction
OT  - Hypertrophie benigne de la prostate
OT  - Inhibiteurs de la 5-alpha-reductase
OT  - Inhibiteurs de la PDE5
OT  - Lower urinary tract symptoms
OT  - PDE5 inhibitors
OT  - Symptomes du bas appareil urinaire
OT  - Tadalafil
OT  - Troubles de l'ejaculation
EDAT- 2015/01/22 06:00
MHDA- 2015/12/29 06:00
CRDT- 2015/01/22 06:00
PHST- 2014/07/21 00:00 [received]
PHST- 2014/11/21 00:00 [revised]
PHST- 2014/12/18 00:00 [accepted]
PHST- 2015/01/22 06:00 [entrez]
PHST- 2015/01/22 06:00 [pubmed]
PHST- 2015/12/29 06:00 [medline]
AID - S1166-7087(14)00690-3 [pii]
AID - 10.1016/j.purol.2014.12.003 [doi]
PST - ppublish
SO  - Prog Urol. 2015 Mar;25(3):115-27. doi: 10.1016/j.purol.2014.12.003. Epub 2015 Jan 
      17.